

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 June 2025 (12.06.2025)

(10) International Publication Number
WO 2025/121445 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/JP2024/080221

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/JP2023/044949

08 December 2023 (08.12.2023) JP

PCT/JP2024/080140

08 August 2024 (08.08.2024) JP

(71) Applicant: **ASTELLAS PHARMA INC.** [JP/JP]; 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP).

(72) Inventors: **TANAKA, Hiroaki**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP). **NAKAZAWA, Taisuke**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP).

(74) Agent: **YAMAMOTO, Osamu** et al.; YUASA AND HARA, Section 206, Shin-Otemachi Bldg., 2-1, Otemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2

(57) Abstract: The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and agents stabilizing or increasing the expression of CLDN18.2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.



WO 2025/121445 A1